Intrachromosomal amplification of chromosome 21 in Korean pediatric patients with B-cell precursor acute lymphoblastic leukemia in a single institution.
- Author:
Mina YANG
1
;
Eun Sang YI
;
Hee Jin KIM
;
Keon Hee YOO
;
Hong Hoe KOO
;
Sun Hee KIM
Author Information
- Publication Type:Original Article
- Keywords: iAMP21; Childhood BCP-ALL; FISH
- MeSH: B-Lymphocytes*; Child; Chromosomes, Human, Pair 21*; Cytogenetics; Disease-Free Survival; Fluorescence; Humans; In Situ Hybridization; Incidence; Leukocyte Count; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma*; Prognosis; Recurrence; Survival Rate
- From:Blood Research 2017;52(2):100-105
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Intrachromosomal amplification of chromosome 21 (iAMP21), defined as the presence of three or more RUNX1 signals on one marker chromosome, is a distinct cytogenetic subgroup of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is known to have a poor prognosis when treated with standard therapy. The aim of this study was to evaluate the clinical characteristics of Korean children with iAMP21. METHODS: The cytogenetic data from BCP-ALL children were reviewed. The ETV6/RUNX1 ES Dual Color Probe was used for fluorescence in situ hybridization (FISH). RESULTS: In total, 295 children were included. Of these, 10 patients (3.4%) had iAMP21. The median age of iAMP21 patients was 9 years, and the median value of white blood cell count was 5.09×10⁹/L. Slow early treatment response was observed more in iAMP21 patients. Patients with iAMP21 had a higher incidence of relapse and worse survival rates. In patients with iAMP21, the estimated 10-year cumulative incidence of relapse was 53.3%. The estimated 10-year event-free survival and overall survival rate were 46.7% and 64.8%, respectively. Most cases of leukemic relapse developed in the late period (median, 43 mo). In multivariate analysis, high risk group was the only factor that had a significant impact on death. CONCLUSION: The existence of iAMP21 was related to delayed treatment response and was likely to affect increased relapse and death in the late period. Further studies are needed to reveal its effect on BCP-ALL treatment outcomes and its role as an independent prognostic factor.
